First Biotherapeutics Co., Ltd. (CEO Jae-eun Kim, hereinafter referred to as "First Bio") announced on the 30th that it has joined the "NVIDIA Inception" program, a startup support program by NVIDIA, a global leader in artificial intelligence (AI). Through this Inception program, First Bio plans to refine its AI model and further solidify its R&D process for developing innovative new drugs.
NVIDIA Inception is a global program that helps promising startups accelerate technological innovation in AI, data science, and high-performance computing (HPC). Selected companies are provided with access to the latest software development tools (SDKs), high-performance GPU hardware, professional training, technical seminars, and connections with global venture capitalists.
FirstBio, a leading domestic biotech specializing in small molecule-based drug development, is advancing new drug discovery through integration with AI technology. By applying AI models to its hit molecule discovery and lead compound optimization platforms, the company is not only enhancing drug discovery efficiency but also expanding the potential for discovering innovative new compounds that would be difficult to discover using conventional methods.
FirstBio plans to integrate NVIDIA's SDK technology into its platform to further enhance the accuracy and predictive reliability of drug design. Specifically, FirstBio plans to apply NVIDIA's BioNeMo platform to protein structure prediction and candidate generation, enhancing the efficiency and innovation of the new drug development workflow. Furthermore, FirstBio plans to improve the accuracy of its AI models through technical feedback with NVIDIA developers.
In addition, the company plans to proactively secure the latest technology trends and strategic collaboration opportunities by actively participating in international AI developer conferences such as Inception member-only technology seminars and NVIDIA GTC, as well as global community events.
CEO Kim Jae-eun said, “FirstBio is opening a new paradigm that has both accuracy and speed in new drug development by building AI fusion technology based on pharmaceutical knowledge,” and “We will work with NVIDIA, a leader in AI infrastructure, to increase the reliability of drug discovery and maximize R&D efficiency.”
- See more related articles
You must be logged in to post a comment.